$FBIO
Fortress Biotech, Inc. Stock $fbio

$fbio Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-K Financial Statement

#000114420419014617 Filed on March 18, 2019

Income Statement

Concept	2019 Q1	2018 Q4	2018 Q3
Revenue	$6.477M	$8.991M	$5.173M
YoY Change	9.72%	19.2%	105.28%
Cost Of Revenue	$1.884M	$1.580M	$1.410M
YoY Change	27.99%	-12.71%	179.21%
Gross Profit	$4.593M	$7.410M	$3.770M
YoY Change	3.66%	-105.84%	87.1%
Gross Profit Margin	70.91%	82.42%	72.88%
Selling, General & Admin	$13.48M	$14.58M	$12.18M
YoY Change	-17.36%	1.18%	-19.36%
% of Gross Profit	293.49%	196.76%	323.08%
Research & Development	$23.27M	$25.05M	$19.79M
YoY Change	-6.75%	73.84%
% of Gross Profit	506.71%	338.06%	524.93%
Depreciation & Amortization	$481.0K	$740.0K	$550.0K
YoY Change	145.41%	-161.67%	175.0%
% of Gross Profit	10.47%	9.99%	14.59%
Operating Expenses	$39.09M	$39.63M	$88.58M
YoY Change	-2.47%	-135.89%	11.44%
Operating Profit	-$32.61M	-$41.21M	-$33.38M
YoY Change	-4.58%	34.59%	4.97%
Interest Expense	$1.847M	-$3.220M	$2.228M
YoY Change	-11.33%	-55.03%	-30.81%
% of Operating Profit
Other Income/Expense, Net	$16.35M		-$2.754M
YoY Change	-930.1%		-25.65%
Pretax Income	-$16.26M	-$34.63M	-$27.64M
YoY Change	-55.02%	46.12%	-23.86%
Income Tax			$944.0K
% Of Pretax Income
Net Earnings	$1.392M	-$24.88M	-$16.64M
YoY Change	-106.62%	138.93%	-38.64%
Net Earnings / Revenue	21.49%	-276.72%	-321.63%
Basic Earnings Per Share	$0.03
Diluted Earnings Per Share	$0.02	-$564.3K	-$371.3K
COMMON SHARES
Basic Shares Outstanding	48.51M	56.68M shares
Diluted Shares Outstanding	63.81M

Balance Sheet

Concept	2019 Q1	2018 Q4	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$121.5M	$83.10M	$125.1M
YoY Change	-26.5%	-36.56%	-19.91%
Cash & Equivalents	$116.4M	$65.51M	$95.87M
Short-Term Investments	$5.000M	$17.60M	$29.20M
Other Short-Term Assets	$4.300M	$19.80M	$14.40M
YoY Change	-71.9%	-54.59%	23.08%
Inventory	$629.0K	$678.0K	$674.0K
Prepaid Expenses
Receivables	$8.022M	$5.498M	$5.431M
Other Receivables	$2.200M	$2.100M	$13.90M
Total Short-Term Assets	$136.5M	$111.2M	$159.5M
YoY Change	-31.78%	-39.29%	-13.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.83M	$12.02M	$14.64M
YoY Change	458.42%	68.9%	510.85%
Goodwill			$18.65M
YoY Change			0.0%
Intangibles
YoY Change
Long-Term Investments	$11.10M	$0.00	$0.00
YoY Change	753.85%	-100.0%
Other Assets	$1.225M	$276.0K	$821.0K
YoY Change	30.88%	6.98%	137.28%
Total Long-Term Assets	$63.99M	$29.79M	$65.40M
YoY Change	-1.43%	-52.55%	7.21%
TOTAL ASSETS
Total Short-Term Assets	$136.5M	$111.2M	$159.5M
Total Long-Term Assets	$63.99M	$29.79M	$65.40M
Total Assets	$200.5M	$141.0M	$224.9M
YoY Change	-24.35%	-42.67%	-8.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$29.30M	$34.20M	$37.50M
YoY Change	-34.6%	23.91%	17.19%
Accrued Expenses	$20.33M	$16.36M	$20.37M
YoY Change	-6.39%	-7.21%	22.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$9.300M	$19.10M	$19.70M
YoY Change	-26.77%	44.7%	51.54%
Total Short-Term Liabilities	$48.96M	$55.61M	$70.78M
YoY Change	-38.26%	-22.15%	3.43%
LONG-TERM LIABILITIES
Long-Term Debt	$73.60M	$60.40M	$64.50M
YoY Change	0.27%	22.52%	27.22%
Other Long-Term Liabilities	$2.276M	$5.211M	$4.961M
YoY Change	-52.17%	9.96%	4.75%
Total Long-Term Liabilities	$2.276M	$5.211M	$4.961M
YoY Change	-52.17%	9.96%	4.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$48.96M	$55.61M	$70.78M
Total Long-Term Liabilities	$2.276M	$5.211M	$4.961M
Total Liabilities	$149.8M	$121.3M	$140.3M
YoY Change	-4.89%	-3.35%	13.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$394.9M	-$396.3M	-$371.4M
YoY Change	18.53%	26.96%	23.09%
Common Stock	$63.00K	$58.00K	$56.00K
YoY Change	21.15%	13.73%	9.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$20.82M	$1.852M	$37.77M
YoY Change
Total Liabilities & Shareholders Equity	$200.5M	$141.0M	$224.9M
YoY Change	-24.35%	-42.67%	-8.23%

Cashflow Statement

Concept	2019 Q1	2018 Q4	2018 Q3
OPERATING ACTIVITIES
Net Income	$1.392M	-$24.88M	-$16.64M
YoY Change	-106.62%	138.93%	-38.64%
Depreciation, Depletion And Amortization	$481.0K	$740.0K	$550.0K
YoY Change	145.41%	-161.67%	175.0%
Cash From Operating Activities	-$25.33M	-$22.16M	-$24.76M
YoY Change	-9.05%	6.18%	-1.28%
INVESTING ACTIVITIES
Capital Expenditures	$300.0K	-$1.540M	-$2.130M
YoY Change	-60.78%	-48.84%	287.27%
Acquisitions
YoY Change
Other Investing Activities	$24.45M	$15.06M	$11.47M
YoY Change	-2363.89%	71.33%	-147.22%
Cash From Investing Activities	$24.15M	$13.52M	$9.330M
YoY Change	-1412.39%	133.91%	-137.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$13.10M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	52.11M	-1.690M	9.960M
YoY Change	31.42%	-108.18%	-41.89%
NET CHANGE
Cash From Operating Activities	-25.33M	-22.16M	-24.76M
Cash From Investing Activities	24.15M	13.52M	9.330M
Cash From Financing Activities	52.11M	-1.690M	9.960M
Net Change In Cash	50.94M	-10.33M	-5.470M
YoY Change	410.84%	-285.46%	-83.31%
FREE CASH FLOW
Cash From Operating Activities	-$25.33M	-$22.16M	-$24.76M
Capital Expenditures	$300.0K	-$1.540M	-$2.130M
Free Cash Flow	-$25.63M	-$20.62M	-$22.63M
YoY Change	-10.43%	15.45%	-7.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2018Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	336000
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	973000
CY2018Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	4567000
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	4072000
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000
CY2018Q4	fbio	Preferred Stock Shares Designated PreferredStockSharesDesignated	5000000
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1000000
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000
CY2017Q4	fbio	Preferred Stock Shares Designated PreferredStockSharesDesignated	5000000
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1000000
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1000000
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1000000
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57845447
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50991285
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57845447
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50991285
CY2018Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	744322
CY2017Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	158015
CY2018	fbio	Sales Revenue Product Services Net SalesRevenueProductServicesNet	23376000
CY2017	fbio	Sales Revenue Product Services Net SalesRevenueProductServicesNet	15520000
CY2017	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	1725000
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6125000
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3658000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	83333000
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48322000
CY2018	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	682000
CY2017	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	368000
CY2018	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	437000
CY2017	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	-457000
CY2018	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2017	us-gaap	Impairment Of Investments ImpairmentOfInvestments	250000
CY2017	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	226000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	750000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	314000
CY2017	us-gaap	Dividends Preferred Stock DividendsPreferredStock	299000
CY2017	fbio	Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance	0
CY2018	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	15012000
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	198000
CY2018	fbio	Adjustments To Additional Paid In Capital Stock Issued For License Expenses AdjustmentsToAdditionalPaidInCapitalStockIssuedForLicenseExpenses	276000
CY2018	fbio	Adjustments To Additional Paid In Capital Subsidiary Public Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering	22668000
CY2018	fbio	Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance	0
CY2018	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	4050000
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	53371000
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	50897000
CY2017	us-gaap	Operating Expenses OperatingExpenses	107041000
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-89796000
CY2017	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-32960000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-66876000
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41658733
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65508000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94952000
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	16074000
CY2017Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	16006000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	81582000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110958000
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	82968000
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	27000
CY2017	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0
CY2017	fbio	Stock Issued During Period Value Preferred Stock StockIssuedDuringPeriodValuePreferredStock	22196000
CY2017	fbio	Adjustments To Additional Paid In Capital Stock Issued For License Expenses AdjustmentsToAdditionalPaidInCapitalStockIssuedForLicenseExpenses	1727000
CY2017	fbio	Adjustments To Additional Paid In Capital Stock Subsidiaries Stock Issued For Research And Development Expenses AdjustmentsToAdditionalPaidInCapitalStockSubsidiariesStockIssuedForResearchAndDevelopmentExpenses	50000
CY2017	fbio	Adjustments To Additional Paid In Capital Stock Issued For Settlement AdjustmentsToAdditionalPaidInCapitalStockIssuedForSettlement	2062000
CY2017	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	191000
CY2017	fbio	Adjustments To Additional Paid In Capital Stock Issued For Research And Development Expenses AdjustmentsToAdditionalPaidInCapitalStockIssuedForResearchAndDevelopmentExpenses	200000
CY2017	fbio	Adjustments To Additional Paid In Capital Subsidiary Public Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering	95116000
CY2017	fbio	Adjustments To Additional Paid In Capital Debt Discount Related To Opus Credit Facility AdjustmentsToAdditionalPaidInCapitalDebtDiscountRelatedToOpusCreditFacility	201000
CY2018	fbio	Percentage Of Tax Benefit Likely Of Being Realized PercentageOfTaxBenefitLikelyOfBeingRealized	0.5
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	16100000
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	16000000
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3100000
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1300000
CY2018Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.17
CY2018Q4	us-gaap	Pledged Assets Separately Reported Loans Pledged As Collateral At Fair Value PledgedAssetsSeparatelyReportedLoansPledgedAsCollateralAtFairValue	1200000
CY2017Q4	us-gaap	Pledged Assets Separately Reported Loans Pledged As Collateral At Fair Value PledgedAssetsSeparatelyReportedLoansPledgedAsCollateralAtFairValue	1100000
CY2018	us-gaap	Dividends Preferred Stock DividendsPreferredStock	2344000
CY2017	us-gaap	Profit Loss ProfitLoss	-99836000
CY2018	us-gaap	Depreciation Depreciation	1393000
CY2017	us-gaap	Depreciation Depreciation	726000
CY2018	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2419000
CY2018	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	666000
CY2017	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	534000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	15012000
CY2018	fbio	Issuance Of Subsidiaries Common Stock For Research And Development Expenses IssuanceOfSubsidiariesCommonStockForResearchAndDevelopmentExpenses	0
CY2017	fbio	Issuance Of Subsidiaries Common Stock For Research And Development Expenses IssuanceOfSubsidiariesCommonStockForResearchAndDevelopmentExpenses	50000
CY2018	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	-1390000
CY2017	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	4164000
CY2018	fbio	Issuance Of Common Stock For Interest Expense IssuanceOfCommonStockForInterestExpense	495000
CY2017	fbio	Issuance Of Common Stock For Interest Expense IssuanceOfCommonStockForInterestExpense	500000
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5928000
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	507000
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-32000
CY2018	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	1477000
CY2017	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	-1172000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3000
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4011000
CY2017	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	10651000
CY2018	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-23000
CY2017	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	172000
CY2018	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	917000
CY2017	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	176000
CY2018	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	-572000
CY2017	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	602000
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1434000
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1625000
CY2018Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5843000
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5279000
CY2018Q4	fbio	Accrued Expenses Related Party AccruedExpensesRelatedParty	0
CY2017Q4	fbio	Accrued Expenses Related Party AccruedExpensesRelatedParty	95000
CY2018Q4	fbio	Accrued Expenses Releted To Dr Falk Pharma Milestone AccruedExpensesReletedToDrFalkPharmaMilestone	300000
CY2017Q4	fbio	Accrued Expenses Releted To Dr Falk Pharma Milestone AccruedExpensesReletedToDrFalkPharmaMilestone	3059000
CY2018Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1108000
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1411000
CY2018Q4	fbio	Accrued Coupon Expense Current AccruedCouponExpenseCurrent	838000
CY2017Q4	fbio	Accrued Coupon Expense Current AccruedCouponExpenseCurrent	1087000
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1327000
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1030000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16360000
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17632000
CY2018Q4	fbio	Deferred Rent And Long Term Lease Abandonment Non Current DeferredRentAndLongTermLeaseAbandonmentNonCurrent	5211000
CY2017Q4	fbio	Deferred Rent And Long Term Lease Abandonment Non Current DeferredRentAndLongTermLeaseAbandonmentNonCurrent	4739000
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5211000
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4739000
CY2017	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	3365000
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	648000
CY2018	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	52604000
CY2017	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	56091000
CY2018	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	71002000
CY2017	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	20089000
CY2018	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits	0
CY2018	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	154000
CY2017	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	25000000
CY2018	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0
CY2017	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2804000
CY2018	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	2344000
CY2017	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	299000
CY2018	fbio	Proceeds From Issuance Of At Market Offering ProceedsFromIssuanceOfAtMarketOffering	7274000
CY2017	fbio	Proceeds From Issuance Of At Market Offering ProceedsFromIssuanceOfAtMarketOffering	0
CY2018	fbio	Payment Of Cost Related To Atthemarket Offering PaymentOfCostRelatedToAtthemarketOffering	257000
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	5045000
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14583000
CY2017	fbio	Payment Of Cost Related To Atthemarket Offering PaymentOfCostRelatedToAtthemarketOffering	0
CY2018	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	23011000
CY2017	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	95117000
CY2018	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	343000
CY2017	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	0
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	27000
CY2018	fbio	Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan	198000
CY2017	fbio	Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan	191000
CY2018	fbio	Payment Of Nsc Note PaymentOfNscNote	0
CY2017	fbio	Payment Of Nsc Note PaymentOfNscNote	3608000
CY2018	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
CY2017	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	9914000
CY2018	fbio	Payment Of Debt Issuance Costs Associated With Subsidiary Convertible Notes PaymentOfDebtIssuanceCostsAssociatedWithSubsidiaryConvertibleNotes	0
CY2017	fbio	Payment Of Debt Issuance Costs Associated With Subsidiary Convertible Notes PaymentOfDebtIssuanceCostsAssociatedWithSubsidiaryConvertibleNotes	104000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82106000
CY2018	us-gaap	Interest Paid Net InterestPaidNet	4448000
CY2017	us-gaap	Interest Paid Net InterestPaidNet	207000
CY2018	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0
CY2017	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	750000
CY2018	us-gaap	Stock Issued1 StockIssued1	0
CY2017	us-gaap	Stock Issued1 StockIssued1	2062000
CY2018	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0
CY2017	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	201000
CY2018	fbio	Unpaid Debt Offering Cost UnpaidDebtOfferingCost	0
CY2017	fbio	Unpaid Debt Offering Cost UnpaidDebtOfferingCost	58000
CY2018	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0
CY2017	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	314000
CY2018	fbio	Issue Of Common Stock For Acquiring License Value IssueOfCommonStockForAcquiringLicenseValue	0
CY2017	fbio	Issue Of Common Stock For Acquiring License Value IssueOfCommonStockForAcquiringLicenseValue	1682000
CY2018Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	4903000
CY2018Q4	us-gaap	Notes Payable NotesPayable	79503000
CY2017Q4	us-gaap	Notes Payable NotesPayable	62499000
CY2018Q4	us-gaap	Long Term Debt LongTermDebt	84406000
CY2017Q4	us-gaap	Long Term Debt LongTermDebt	67544000
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8287000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2564000
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1171000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12019000
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7116000
CY2018	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	0
CY2017	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	28355000
CY2018	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0
CY2017	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	81000
CY2018	us-gaap	Proceeds From Unsecured Lines Of Credit ProceedsFromUnsecuredLinesOfCredit	0
CY2017	us-gaap	Proceeds From Unsecured Lines Of Credit ProceedsFromUnsecuredLinesOfCredit	2500000
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17682146
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13701104
CY2017	fbio	Class Of Warrant Or Right Exercise Price Description ClassOfWarrantOrRightExercisePriceDescription	the exercise price will be $75 million dollars divided by the total number of fully-diluted shares of Common Stock outstanding immediately prior to exercise of the warrant, giving effect to the assumed conversion of all options, warrants, and convertible securities of the Company .
CY2018	fbio	Reimbursement Of Cost Recognized As Revenue ReimbursementOfCostRecognizedAsRevenue	35000
CY2017	fbio	Reimbursement Of Cost Recognized As Revenue ReimbursementOfCostRecognizedAsRevenue	600000
CY2018Q4	us-gaap	Inventory Net InventoryNet	678000
CY2017Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	222000
CY2018Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1232000
CY2018	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	15012000
CY2017	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	13403000
CY2016	us-gaap	Debt Instrument Convertible Terms Of Conversion Feature DebtInstrumentConvertibleTermsOfConversionFeature	(a) a discount to the price per share being paid in the Sale of Helocyte equal to 33% or (b) a conversion price per share based on a pre-sale valuation of $50.0 million divided by the fully-diluted common stock of Helocyte immediately prior to the Sale of Helocyte (excluding the notes).
CY2015Q1	us-gaap	Notes Payable NotesPayable	10000000
CY2015Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	900000
CY2018Q1	us-gaap	Debt Instrument Term DebtInstrumentTerm	P36M
CY2018	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	75680000
CY2018Q4	us-gaap	Minority Interest MinorityInterest	17891000
CY2017	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	100889000
CY2017Q4	us-gaap	Minority Interest MinorityInterest	67929000
CY2018Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	10905000
CY2017Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	1390000
CY2017Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1390000
CY2017Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	15068000
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	21833000
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-1390000
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	437000
CY2018	fbio	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Derivative Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisDerivativeLiabilityGainLossIncludedInEarnings	682000
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	10905000
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	20941000
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	9914000
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	1064000
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	226000
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-457000
CY2017	fbio	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Derivative Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisDerivativeLiabilityGainLossIncludedInEarnings	-8391000
CY2017	fbio	Fair Value Assumptions Probability Of Business Combination FairValueAssumptionsProbabilityOfBusinessCombination	0.4653
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5498000
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7758000
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	17604000
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	36002000
CY2017Q4	us-gaap	Inventory Net InventoryNet	171000
CY2018Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	2095000
CY2017Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	618000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6735000
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5732000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	111207000
CY2017Q4	us-gaap	Assets Current AssetsCurrent	183181000
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	16074000
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	16006000
CY2018Q4	us-gaap	Long Term Investments LongTermInvestments	0
CY2017Q4	us-gaap	Long Term Investments LongTermInvestments	1390000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1417000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	883000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	276000
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	258000
CY2018Q4	us-gaap	Assets Assets	140993000
CY2017Q4	us-gaap	Assets Assets	245950000
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	34067000
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	27412000
CY2018Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	149000
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1351080
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P3Y11M12D
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	315000
CY2018Q4	fbio	Due To Related Parties Interest Expenses Current DueToRelatedPartiesInterestExpensesCurrent	97000
CY2016Q3	us-gaap	Legal Fees LegalFees	25000000
CY2017Q4	fbio	Due To Related Parties Interest Expenses Current DueToRelatedPartiesInterestExpensesCurrent	669000
CY2017	fbio	Noncash Or Part Noncash Acquisition Fixed Assets Acquired Payable NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredPayable	982000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	25000
CY2018Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	25.00
CY2017Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	25.00
CY2018Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	9164000
CY2017Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	8528000
CY2018Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	9914000
CY2017Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	4700000
CY2018Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	991000
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	309000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	55614000
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	71438000
CY2018Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	60425000
CY2017Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	39212000
CY2018Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	0
CY2017Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	10059000
CY2018Q4	us-gaap	Liabilities Liabilities	121250000
CY2017Q4	us-gaap	Liabilities Liabilities	125448000
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	58000
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	51000
CY2018Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	659000
CY2017Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	500000
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	364148000
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-312127000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	52573000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	140993000
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	245950000
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.94
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.61
CY2016Q3	fbio	Class Of Warrant Or Right Value Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights	1500000
CY2017	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	4164000
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1110501
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.78
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.75
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1085501
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.75
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P2Y11M5D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P2Y11M5D
CY2017	us-gaap	Revenues Revenues	17245000
CY2018Q4	fbio	Revenue Recognition Milestone Method Payments Due RevenueRecognitionMilestoneMethodPaymentsDue	2000000
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10000000
CY2015Q3	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	136830
CY2015Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	600000
CY2018	fbio	Payment Of Upfront Fees PaymentOfUpfrontFees	1000000
CY2017Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	43292
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018	fbio	Change In Fair Value Of Subsidiaries Assets And Liabilities ChangeInFairValueOfSubsidiariesAssetsAndLiabilities	0
CY2017	fbio	Change In Fair Value Of Subsidiaries Assets And Liabilities ChangeInFairValueOfSubsidiariesAssetsAndLiabilities	104000
CY2018Q4	us-gaap	Time Deposits At Carrying Value TimeDepositsAtCarryingValue	27600000
CY2017Q4	us-gaap	Time Deposits At Carrying Value TimeDepositsAtCarryingValue	50000000
CY2018Q3	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	-3030000
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-24880000
CY2018	fbio	Adjustments To Additional Paid In Capital Subsidiary At Market Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering	7747000
CY2018	fbio	Stock Issued During Period Value Cash Less Exercise Of Warrants StockIssuedDuringPeriodValueCashLessExerciseOfWarrants	181000
CY2018	fbio	Issuance Of Common Stock For At Market Offering IssuanceOfCommonStockForAtMarketOffering	7017000
CY2018Q4	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	-2410000
CY2018Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	17200000
CY2018Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	14105000
CY2018Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	11949000
CY2018Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	14535000
CY2018	fbio	Adjustments To Additional Paid In Capital Capital Contribution For2017 Bonuses AdjustmentsToAdditionalPaidInCapitalCapitalContributionFor2017Bonuses	1000000
CY2018	fbio	Common Shares Issuable For Subordinated Note Financial Interest Expenses CommonSharesIssuableForSubordinatedNoteFinancialInterestExpenses	495000
CY2018	fbio	Common Shares Issued For Subordinated Note Financial Interest Expenses CommonSharesIssuedForSubordinatedNoteFinancialInterestExpenses	1472000
CY2018	fbio	Common Shares Issued For Opus Interest Expenses In Value CommonSharesIssuedForOpusInterestExpensesInValue	859000
CY2018	fbio	Common Stock Issued For Services Of Opus Interest Expenses CommonStockIssuedForServicesOfOpusInterestExpenses	-859000
CY2017	fbio	Common Stock Issued For Services Of Opus Interest Expenses CommonStockIssuedForServicesOfOpusInterestExpenses	0
CY2018	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000
CY2017	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000
CY2018Q1	us-gaap	Revenues Revenues	5903000
CY2018Q2	us-gaap	Revenues Revenues	6815000
CY2018Q3	us-gaap	Revenues Revenues	5173000
CY2018Q4	us-gaap	Revenues Revenues	8991000
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-40075000
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-32213000
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-33378000
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-41213000
CY2018Q1	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	-1969000
CY2018Q2	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	-3394000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-21018000
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-21611000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-16638000
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.49
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.50
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.55
CY2017Q1	us-gaap	Revenues Revenues	2778000
CY2017Q2	us-gaap	Revenues Revenues	4404000
CY2017Q3	us-gaap	Revenues Revenues	2520000
CY2017Q4	us-gaap	Revenues Revenues	7543000
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-19125000
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-25495000
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-31799000
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-30622000
CY2017Q1	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	-1248000
CY2017Q2	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	-1674000
CY2017Q3	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	-3067000
CY2017Q4	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	-1728000
CY2017Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	2580000
CY2017Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	5584000
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1200000
CY2017Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	9191000
CY2017Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	15605000
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-11982000
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-17365000
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-27116000
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-10413000
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.67
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	3070000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	3289000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	3084000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	3084000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	3137000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	23466000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	39130000
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1700000
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company’s consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q4	us-gaap	Land Subject To Ground Leases LandSubjectToGroundLeases	6100
CY2017Q4	fbio	Deferred Tax Assets Amortization Of Upfront Fees DeferredTaxAssetsAmortizationOfUpfrontFees	13648000
CY2017Q4	fbio	Deferred Tax Assets Amortization Of In Process Research And Development DeferredTaxAssetsAmortizationOfInProcessResearchAndDevelopment	557000
CY2012Q4	us-gaap	Land Subject To Ground Leases LandSubjectToGroundLeases	8700
CY2017Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	55000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	10682000
CY2014Q4	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2500000
CY2015Q4	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000
CY2018	fbio	Proceeds From Issuance Of Subsidiaries At Market Offering ProceedsFromIssuanceOfSubsidiariesAtMarketOffering	7981000
CY2017	fbio	Proceeds From Issuance Of Subsidiaries At Market Offering ProceedsFromIssuanceOfSubsidiariesAtMarketOffering	0
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1074000
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	439000
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1513000
CY2018	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reclassifications</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Certain prior period amounts may have been reclassified to conform to the current year presentation.</div><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	23376000
CY2017	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	15520000
CY2017	us-gaap	Payments For Mortgage Deposits PaymentsForMortgageDeposits	251000
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	71616000
CY2018	fbio	Payment Of Cost Related To Subsidiaries At The Market Offering PaymentOfCostRelatedToSubsidiariesAtTheMarketOffering	234000
CY2017	fbio	Payment Of Cost Related To Subsidiaries At The Market Offering PaymentOfCostRelatedToSubsidiariesAtTheMarketOffering	0
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	181000
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2018	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	21707000
CY2017	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	0
CY2018	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	1868000
CY2017	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	0
CY2018	fbio	Common Shares Issued For2017 Subordinated Note Financing Interest Expense CommonSharesIssuedFor2017SubordinatedNoteFinancingInterestExpense	500000
CY2017	fbio	Common Shares Issued For2017 Subordinated Note Financing Interest Expense CommonSharesIssuedFor2017SubordinatedNoteFinancingInterestExpense	0
CY2012	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	5166000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	7376000
CY2017Q4	fbio	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	75000
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	109120000
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	101645000
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	7475000
CY2017Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	685000
CY2017Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	3321000
CY2017Q4	us-gaap	Deferred Tax Liabilities Parents Basis In Discontinued Operation DeferredTaxLiabilitiesParentsBasisInDiscontinuedOperation	3469000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.08
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.01
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.02
CY2017	fbio	Effective Income Tax Rate Reconciliation Provision For Return EffectiveIncomeTaxRateReconciliationProvisionForReturn	0.01
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.01
CY2017	fbio	Effective Income Tax Rate Reconciliation Change In Federal Rate Percent EffectiveIncomeTaxRateReconciliationChangeInFederalRatePercent	-0.43
CY2017	fbio	Effective Income Tax Rate Reconciliation Change In State Rate Percent EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent	0.02
CY2017	fbio	Effective Income Tax Rate Reconciliation Intercompany Elimination Adjustments Percent EffectiveIncomeTaxRateReconciliationIntercompanyEliminationAdjustmentsPercent	-0.03
CY2017	fbio	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantsPercent	0.03
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.07
CY2017Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	29283000
CY2018Q3	us-gaap	Land Subject To Ground Leases LandSubjectToGroundLeases	3681
CY2017Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	37948000
CY2018Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	0
CY2018	fbio	Discontinued Operation Gain Loss On Disposal Of National Net Of Tax DiscontinuedOperationGainLossOnDisposalOfNationalNetOfTax	2333000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	0.04
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.02
CY2018Q4	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	100000000
CY2017Q4	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	100000000
CY2018Q1	fbio	Debt Instrument Maturity Period Extention Description DebtInstrumentMaturityPeriodExtentionDescription	The Company may also use the proceeds to finance its subsidiaries. The notes mature 36 months from issuance, provided that during the first 24 months the Company may extend the maturity date by six months
CY2018Q1	fbio	Debt Instrument Change In Periodic Interest Payment Description DebtInstrumentChangeInPeriodicInterestPaymentDescription	Interest on the note is 8% payable quarterly during the first 24 months (or the first 30 months if the note is extended) and monthly during the last 12 months
CY2018Q4	fbio	Dividends Payable Receivable Current DividendsPayableReceivableCurrent	0
CY2017Q4	fbio	Dividends Payable Receivable Current DividendsPayableReceivableCurrent	0
CY2018	fbio	Annual Management Services Agreement Fee Income Expense AnnualManagementServicesAgreementFeeIncomeExpense	0
CY2017	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	0
CY2018	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	0
CY2017	fbio	Discontinued Operation Gain Loss On Disposal Of National Net Of Tax DiscontinuedOperationGainLossOnDisposalOfNationalNetOfTax	0
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	-4408000
CY2018	fbio	Disposal Of National DisposalOfNational	-5375000
CY2018Q3	fbio	Common Stock Redemption Price Per Share CommonStockRedemptionPricePerShare	11.00
CY2017Q2	us-gaap	Land Subject To Ground Leases LandSubjectToGroundLeases	2295
CY2015Q4	fbio	Lease Expiration Period LeaseExpirationPeriod	P5Y
CY2018Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	13089000
CY2017Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	37116000
CY2018Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0
CY2018	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-13469000
CY2017	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-2323000
CY2018	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-11136000
CY2017	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-2323000
CY2018	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-3.01
CY2017	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-2.34
CY2018	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.26
CY2017	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.06
CY2017Q4	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.5839375
CY2018	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1841774
CY2017Q4	fbio	Percentage Of Placement Of Agent Fee PercentageOfPlacementOfAgentFee	0.030
CY2018Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5290000
CY2018	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	9783000
CY2017	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0
CY2018	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	404000
CY2017	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2018	fbio	Receivables Of Contribution Of Capital For Bonus ReceivablesOfContributionOfCapitalForBonus	1000000
CY2017	fbio	Receivables Of Contribution Of Capital For Bonus ReceivablesOfContributionOfCapitalForBonus	0
CY2017	fbio	Percentage Of Placement Of Agent Fee PercentageOfPlacementOfAgentFee	0.1
CY2017Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.50
CY2017Q4	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.09375
CY2017Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25000000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	13176146
CY2017	fbio	Disposal Group Including Discontinued Operation Licenses And Registration DisposalGroupIncludingDiscontinuedOperationLicensesAndRegistration	1726000
CY2018Q4	fbio	Employee Stock Purchase Plan Offering Fair Value Reckoning Percentage EmployeeStockPurchasePlanOfferingFairValueReckoningPercentage	0.85
CY2018Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	643493
CY2018	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	200000
CY2017	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	200000
CY2016Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	53000000
CY2017Q4	us-gaap	Payments For Fees PaymentsForFees	100000
CY2017Q4	us-gaap	Payments For Fees PaymentsForFees	2700000
CY2017Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	125000
CY2017	fbio	Stock Issued For Exercise Of Warrants StockIssuedForExerciseOfWarrants	10000
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	800000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	13900000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	11300000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1900000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	490000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1128750
CY2017Q1	fbio	Sharebased Compensation Arrangement By Sharebased Payment Award Percentage Of Shares Granted SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfSharesGranted	0.01
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	7700000
CY2018Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	6100000
CY2017Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	6.00
CY2018	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	210980000
CY2017	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	170339000
CY2018	fbio	Disposal Group Including Discontinued Operation Commissions Compensation And Fees DisposalGroupIncludingDiscontinuedOperationCommissionsCompensationAndFees	182127000
CY2017	fbio	Disposal Group Including Discontinued Operation Commissions Compensation And Fees DisposalGroupIncludingDiscontinuedOperationCommissionsCompensationAndFees	155187000
CY2018	fbio	Disposal Group Including Discontinued Operation Clearing Fees DisposalGroupIncludingDiscontinuedOperationClearingFees	2400000
CY2017	fbio	Disposal Group Including Discontinued Operation Clearing Fees DisposalGroupIncludingDiscontinuedOperationClearingFees	2343000
CY2018	fbio	Disposal Group Including Discontinued Operation Communications DisposalGroupIncludingDiscontinuedOperationCommunications	3260000
CY2017	fbio	Disposal Group Including Discontinued Operation Communications DisposalGroupIncludingDiscontinuedOperationCommunications	2767000
CY2018	fbio	Disposal Group Including Discontinued Operation Occupancy DisposalGroupIncludingDiscontinuedOperationOccupancy	3755000
CY2017	fbio	Disposal Group Including Discontinued Operation Occupancy DisposalGroupIncludingDiscontinuedOperationOccupancy	4286000
CY2018	fbio	Disposal Group Including Discontinued Operation Licenses And Registration DisposalGroupIncludingDiscontinuedOperationLicensesAndRegistration	2735000
CY2018	fbio	Disposal Group Including Discontinued Operation Professional Fees DisposalGroupIncludingDiscontinuedOperationProfessionalFees	4306000
CY2017	fbio	Disposal Group Including Discontinued Operation Professional Fees DisposalGroupIncludingDiscontinuedOperationProfessionalFees	4531000
CY2018	us-gaap	Disposal Group Including Discontinued Operation Interest Expense DisposalGroupIncludingDiscontinuedOperationInterestExpense	97000
CY2017	us-gaap	Disposal Group Including Discontinued Operation Interest Expense DisposalGroupIncludingDiscontinuedOperationInterestExpense	14000
CY2018	us-gaap	Disposal Group Including Discontinued Operation Depreciation And Amortization DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization	1551000
CY2017	us-gaap	Disposal Group Including Discontinued Operation Depreciation And Amortization DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization	2089000
CY2018	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	8165000
CY2017	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	8808000
CY2018	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	208396000
CY2017	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	181751000
CY2018	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	2584000
CY2017	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-11412000
CY2018	fbio	Disposal Group Including Discontinued Operation Change In Fair Value Of Derivative Liabilities DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfDerivativeLiabilities	0
CY2017	fbio	Disposal Group Including Discontinued Operation Change In Fair Value Of Derivative Liabilities DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfDerivativeLiabilities	304000
CY2018	fbio	Disposal Group Including Discontinued Operation Interest Expense And Financing Fees DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndFinancingFees	0
CY2017	fbio	Disposal Group Including Discontinued Operation Interest Expense And Financing Fees DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndFinancingFees	-1827000
CY2018	fbio	Disposal Group Including Discontinued Operation Change In Fair Value Of Warrants DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfWarrants	-13018000
CY2017	fbio	Disposal Group Including Discontinued Operation Change In Fair Value Of Warrants DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfWarrants	8455000
CY2018	us-gaap	Disposal Group Including Discontinued Operation Other Income DisposalGroupIncludingDiscontinuedOperationOtherIncome	153000
CY2017	us-gaap	Disposal Group Including Discontinued Operation Other Income DisposalGroupIncludingDiscontinuedOperationOtherIncome	16000
CY2018	fbio	Disposal Group Including Discontinued Operation Total Other Expenses Income DisposalGroupIncludingDiscontinuedOperationTotalOtherExpensesIncome	-12865000
CY2017	fbio	Disposal Group Including Discontinued Operation Total Other Expenses Income DisposalGroupIncludingDiscontinuedOperationTotalOtherExpensesIncome	10602000
CY2018	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-10281000
CY2017	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-810000
CY2018	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	3188000
CY2017	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	1513000
CY2018	fbio	Two Thousand And Seventeen Preferred Offering Cost Adjustment TwoThousandAndSeventeenPreferredOfferingCostAdjustment	154000
CY2018Q4	fbio	Disposal Group Including Discontinued Operation Restricted Cash DisposalGroupIncludingDiscontinuedOperationRestrictedCash	0
CY2018	fbio	Dispoal Of National DispoalOfNational	-13558000
CY2017	fbio	Common Shares Issuable For Interest Expenses CommonSharesIssuableForInterestExpenses	500000
CY2017	fbio	Common Shares Issued For Interest Expenses CommonSharesIssuedForInterestExpenses	541000
CY2018	fbio	Settlement Of Restricted Stock Units Into Common Stock SettlementOfRestrictedStockUnitsIntoCommonStock	0
CY2017	fbio	Common Stock Issued For Interest Expenses CommonStockIssuedForInterestExpenses	-541000
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1200000
CY2017	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0
CY2018	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	4408000
CY2017	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0
CY2018	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	281000
CY2017	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	571000
CY2018	us-gaap	Noninterest Expense Transfer Agent And Custodian Fees NoninterestExpenseTransferAgentAndCustodianFees	1700000
CY2018	fbio	Description Of Fee Paid DescriptionOfFeePaid	NSC received a fee of approximately $1.8 million, or 8% on the gross proceeds raised of $23.0 million.
CY2017	fbio	Lease Sharing Agreements Contributions To Property Under Lease LeaseSharingAgreementsContributionsToPropertyUnderLease	163000
CY2018	fbio	Lease Sharing Agreements Contributions To Property Under Lease LeaseSharingAgreementsContributionsToPropertyUnderLease	121000
CY2017Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	6600
CY2018Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	12000
CY2018Q4	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	0
CY2017Q4	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	18963000
CY2018Q4	fbio	Disposal Group Including Discontinued Operation Cash Deposits With Clearing Organizations DisposalGroupIncludingDiscontinuedOperationCashDepositsWithClearingOrganizations	0
CY2017Q4	fbio	Disposal Group Including Discontinued Operation Cash Deposits With Clearing Organizations DisposalGroupIncludingDiscontinuedOperationCashDepositsWithClearingOrganizations	1041000
CY2018Q4	fbio	Disposal Group Including Discontinued Operation Receivables From Broker Dealers And Clearing Organizations DisposalGroupIncludingDiscontinuedOperationReceivablesFromBrokerDealersAndClearingOrganizations	0
CY2017Q4	fbio	Disposal Group Including Discontinued Operation Receivables From Broker Dealers And Clearing Organizations DisposalGroupIncludingDiscontinuedOperationReceivablesFromBrokerDealersAndClearingOrganizations	7395000
CY2018Q4	fbio	Disposal Group Including Discontinued Operation Forgivable Loans Receivable DisposalGroupIncludingDiscontinuedOperationForgivableLoansReceivable	0
CY2017Q4	fbio	Disposal Group Including Discontinued Operation Forgivable Loans Receivable DisposalGroupIncludingDiscontinuedOperationForgivableLoansReceivable	1616000
CY2018Q4	fbio	Disposal Group Including Discontinued Operation Securities Owned At Fair Value DisposalGroupIncludingDiscontinuedOperationSecuritiesOwnedAtFairValue	0
CY2017Q4	fbio	Disposal Group Including Discontinued Operation Securities Owned At Fair Value DisposalGroupIncludingDiscontinuedOperationSecuritiesOwnedAtFairValue	1985000
CY2018Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	13089000
CY2017Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	0
CY2018Q4	us-gaap	Disposal Group Including Discontinued Operation Prepaid And Other Assets Current DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent	0
CY2017Q4	us-gaap	Disposal Group Including Discontinued Operation Prepaid And Other Assets Current DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent	6948000
CY2017Q4	fbio	Disposal Group Including Discontinued Operation Restricted Cash DisposalGroupIncludingDiscontinuedOperationRestrictedCash	1381000
CY2018Q4	us-gaap	Disposal Group Including Discontinued Operation Goodwill Noncurrent DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent	0
CY2017Q4	us-gaap	Disposal Group Including Discontinued Operation Goodwill Noncurrent DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent	18645000
CY2018Q4	us-gaap	Disposal Group Including Discontinued Operation Intangible Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent	0
CY2017Q4	us-gaap	Disposal Group Including Discontinued Operation Intangible Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent	14340000
CY2018Q4	us-gaap	Disposal Group Including Discontinued Operation Other Noncurrent Assets DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets	0
CY2017Q4	us-gaap	Disposal Group Including Discontinued Operation Other Noncurrent Assets DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets	353000
CY2018Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	13089000
CY2017Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	75064000
CY2018Q4	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment Noncurrent DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent	0
CY2017Q4	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment Noncurrent DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent	2397000
CY2018Q4	us-gaap	Disposal Group Including Discontinued Operation Accounts Payable And Accrued Liabilities Current DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent	0
CY2017Q4	us-gaap	Disposal Group Including Discontinued Operation Accounts Payable And Accrued Liabilities Current DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent	8404000
CY2018Q4	fbio	Disposal Group Including Discontinued Operation Accrued Commissions And Payroll Payable DisposalGroupIncludingDiscontinuedOperationAccruedCommissionsAndPayrollPayable	0
CY2017Q4	fbio	Disposal Group Including Discontinued Operation Accrued Commissions And Payroll Payable DisposalGroupIncludingDiscontinuedOperationAccruedCommissionsAndPayrollPayable	10065000
CY2018Q4	fbio	Disposal Group Including Discontinued Operation Contingent Consideration Payable DisposalGroupIncludingDiscontinuedOperationContingentConsiderationPayable	0
CY2017Q4	fbio	Disposal Group Including Discontinued Operation Contingent Consideration Payable DisposalGroupIncludingDiscontinuedOperationContingentConsiderationPayable	311000
CY2018Q4	fbio	Disposal Group Including Discontinued Operation Deferred Clearing And Marketing Credits DisposalGroupIncludingDiscontinuedOperationDeferredClearingAndMarketingCredits	0
CY2017Q4	fbio	Disposal Group Including Discontinued Operation Deferred Clearing And Marketing Credits DisposalGroupIncludingDiscontinuedOperationDeferredClearingAndMarketingCredits	786000
CY2018Q4	fbio	Disposal Group Including Discontinued Operation Securities Sold Not Yet Purchased At Fair Value DisposalGroupIncludingDiscontinuedOperationSecuritiesSoldNotYetPurchasedAtFairValue	0
CY2017Q4	fbio	Disposal Group Including Discontinued Operation Securities Sold Not Yet Purchased At Fair Value DisposalGroupIncludingDiscontinuedOperationSecuritiesSoldNotYetPurchasedAtFairValue	151000
CY2018Q4	fbio	Disposal Group Including Discontinued Operation Warrants Issued And Issuable DisposalGroupIncludingDiscontinuedOperationWarrantsIssuedAndIssuable	0
CY2017Q4	fbio	Disposal Group Including Discontinued Operation Warrants Issued And Issuable DisposalGroupIncludingDiscontinuedOperationWarrantsIssuedAndIssuable	5597000
CY2018Q4	us-gaap	Disposal Group Including Discontinued Operation Other Current Liabilities DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities	0
CY2017Q4	us-gaap	Disposal Group Including Discontinued Operation Other Current Liabilities DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities	3969000
CY2018Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation	0
CY2018Q3	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	3300000
CY2017Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation	29283000
CY2018	fbio	Disposal Group Including Discontinued Operation Effect Of Elimination Entry DisposalGroupIncludingDiscontinuedOperationEffectOfEliminationEntry	-1785000
CY2017	fbio	Disposal Group Including Discontinued Operation Effect Of Elimination Entry DisposalGroupIncludingDiscontinuedOperationEffectOfEliminationEntry	-4147000
CY2018	fbio	Disposal Group Including Discontinued Operation Proceeds From Sale Of Nhld Investments DisposalGroupIncludingDiscontinuedOperationProceedsFromSaleOfNHLDInvestments	9783000
CY2017	fbio	Disposal Group Including Discontinued Operation Proceeds From Sale Of Nhld Investments DisposalGroupIncludingDiscontinuedOperationProceedsFromSaleOfNHLDInvestments	0
CY2018	fbio	Disposal Group Including Discontinued Operation Debt Issuance Costs Of Subordinated Note Financing DisposalGroupIncludingDiscontinuedOperationDebtIssuanceCostsOfSubordinatedNoteFinancing	0
CY2017	fbio	Disposal Group Including Discontinued Operation Debt Issuance Costs Of Subordinated Note Financing DisposalGroupIncludingDiscontinuedOperationDebtIssuanceCostsOfSubordinatedNoteFinancing	2836000
CY2018	fbio	Disposal Group Including Discontinued Operation Debt Issuance Costs Of Subsidiaries Convertible Note DisposalGroupIncludingDiscontinuedOperationDebtIssuanceCostsOfSubsidiariesConvertibleNote	0
CY2017	fbio	Disposal Group Including Discontinued Operation Debt Issuance Costs Of Subsidiaries Convertible Note DisposalGroupIncludingDiscontinuedOperationDebtIssuanceCostsOfSubsidiariesConvertibleNote	991000
CY2018	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	0
CY2017	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-3827000
CY2018Q4	us-gaap	Sale Of Stock Transaction Date SaleOfStockTransactionDate	2018-11-14
CY2019Q1	us-gaap	Sale Of Stock Transaction Date SaleOfStockTransactionDate	2019-02-11
CY2018	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2020-11-30
CY2018Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.50
CY2018	fbio	Adjustments To Additional Paid In Capital At Market Offering Costs AdjustmentsToAdditionalPaidInCapitalAtMarketOfferingCosts	300000
CY2018Q1	us-gaap	Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross	100000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1085501
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.75
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1085501
CY2018Q1	fbio	Sponsor Research Agreement Funding Commitment SponsorResearchAgreementFundingCommitment	900000
CY2017Q4	fbio	Sponsor Research Agreement Funding Commitment SponsorResearchAgreementFundingCommitment	2300000
CY2018	fbio	Additional Annual License Fee AdditionalAnnualLicenseFee	75000
CY2018	us-gaap	Cost Maintenance CostMaintenance	25000
CY2017	us-gaap	Cost Maintenance CostMaintenance	50000
CY2018	fbio	Settlement Of Restricted Shares Units Into Common Stock SettlementOfRestrictedSharesUnitsIntoCommonStock	3000
CY2017	fbio	Settlement Of Restricted Shares Units Into Common Stock SettlementOfRestrictedSharesUnitsIntoCommonStock	2000
CY2017	fbio	Time To Expected Business Combination Or Liquidation TimeToExpectedBusinessCombinationOrLiquidation	0.0005
CY2017	fbio	Fair Values Assumptions Expected Dividend Rate FairValuesAssumptionsExpectedDividendRate	0
CY2018Q1	us-gaap	Research And Development Arrangement Contract To Perform For Others Description And Terms ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms	2 year
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19743000
CY2018Q4	fbio	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	3805000
CY2017Q4	fbio	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	1873000
CY2018Q4	fbio	Accrued Research And Development Expense Milestones AccruedResearchAndDevelopmentExpenseMilestones	200000
CY2017Q4	fbio	Accrued Research And Development Expense Milestones AccruedResearchAndDevelopmentExpenseMilestones	800000
CY2018Q4	fbio	Accrued Research And Development Expense Manufacturing AccruedResearchAndDevelopmentExpenseManufacturing	826000
CY2017Q4	fbio	Accrued Research And Development Expense Manufacturing AccruedResearchAndDevelopmentExpenseManufacturing	1188000
CY2018Q4	fbio	Administration Fee Payable AdministrationFeePayable	39500
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	120502000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-396274000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1852000
CY2018Q4	fbio	Accrued Research And Development Expense Clinical Supplies AccruedResearchAndDevelopmentExpenseClinicalSupplies	160000
CY2017Q4	fbio	Accrued Research And Development Expense Clinical Supplies AccruedResearchAndDevelopmentExpenseClinicalSupplies	85000
CY2018Q4	fbio	Accrued Research And Development Expenselicense Maintenance Fees AccruedResearchAndDevelopmentExpenselicenseMaintenanceFees	519000
CY2017Q4	fbio	Accrued Research And Development Expenselicense Maintenance Fees AccruedResearchAndDevelopmentExpenselicenseMaintenanceFees	100000
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	1104000
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	819000
CY2018	fbio	Interestexpenseandfinancefees Interestexpenseandfinancefees	10340000
CY2017	fbio	Interestexpenseandfinancefees Interestexpenseandfinancefees	7687000
CY2018	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	682000
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	368000
CY2018	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	437000
CY2017	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	-457000
CY2018	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	-1390000
CY2017	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	226000
CY2018	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	68000
CY2017	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	-250000
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10803000
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7717000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-130800000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-97513000
CY2018Q3	us-gaap	Operating Leases Rent Expense Minimum Rentals OperatingLeasesRentExpenseMinimumRentals	94000
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	397408000
CY2018	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	3506000
CY2018	us-gaap	Revenues Revenues	26882000
CY2018	us-gaap	Operating Expenses OperatingExpenses	146879000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-119997000
CY2018	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-57789000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-84147000
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43461978
CY2017	fbio	Dispoal Of National DispoalOfNational	391000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	50648000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	154208000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	50648000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	150381000
CY2018	us-gaap	Profit Loss ProfitLoss	-141936000
CY2017	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3141000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	13403000
CY2018	fbio	Issuance Of Common Stock For Research And Development Expenses IssuanceOfCommonStockForResearchAndDevelopmentExpenses	0
CY2017	fbio	Issuance Of Common Stock For Research And Development Expenses IssuanceOfCommonStockForResearchAndDevelopmentExpenses	200000
CY2018	fbio	Issuance Of Common Stock For Research And Developmentlicenses Acquired Expense IssuanceOfCommonStockForResearchAndDevelopmentlicensesAcquiredExpense	276000
CY2017	fbio	Issuance Of Common Stock For Research And Developmentlicenses Acquired Expense IssuanceOfCommonStockForResearchAndDevelopmentlicensesAcquiredExpense	0
CY2018	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	3774000
CY2018	fbio	Common Stock Issued For Interest Expenses CommonStockIssuedForInterestExpenses	-1472000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2260000
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	17000
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4686000
CY2018	fbio	Increase Decrease Disposal Group Including Discontinued Operation Assets Current IncreaseDecreaseDisposalGroupIncludingDiscontinuedOperationAssetsCurrent	0
CY2017	fbio	Increase Decrease Disposal Group Including Discontinued Operation Assets Current IncreaseDecreaseDisposalGroupIncludingDiscontinuedOperationAssetsCurrent	3189000
CY2018	fbio	Increase Decrease Disposal Group Including Discontinued Operation Assets Noncurrent IncreaseDecreaseDisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	0
CY2017	fbio	Increase Decrease Disposal Group Including Discontinued Operation Assets Noncurrent IncreaseDecreaseDisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	-620000
CY2018	fbio	Increase Decrease Disposal Group Including Discontinued Operation Liabilities Current IncreaseDecreaseDisposalGroupIncludingDiscontinuedOperationLiabilitiesCurrent	0
CY2017	fbio	Increase Decrease Disposal Group Including Discontinued Operation Liabilities Current IncreaseDecreaseDisposalGroupIncludingDiscontinuedOperationLiabilitiesCurrent	9008000
CY2018	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	472000
CY2017	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-284000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-97063000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-77158000
CY2018	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-1785000
CY2017	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-4147000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-98848000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-81305000
CY2018	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	1074000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7082000
CY2018	us-gaap	Payments For Mortgage Deposits PaymentsForMortgageDeposits	1000
CY2017	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits	42000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	9041000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-40224000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18824000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-40224000
CY2018	fbio	Noncash Or Part Noncash Acquisition Fixed Assets Acquired Payable NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredPayable	196000
CY2018	fbio	Unpaid Reserch And Development Licenses Acquired UnpaidReserchAndDevelopmentLicensesAcquired	2700000
CY2017	fbio	Unpaid Reserch And Development Licenses Acquired UnpaidReserchAndDevelopmentLicensesAcquired	755000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	13403000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-29376000
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	28852000
CY2018Q1	fbio	Discontinued Operation Gain Loss On Disposal Of National Net Of Tax DiscontinuedOperationGainLossOnDisposalOfNationalNetOfTax	0
CY2018Q2	fbio	Discontinued Operation Gain Loss On Disposal Of National Net Of Tax DiscontinuedOperationGainLossOnDisposalOfNationalNetOfTax	0
CY2018Q3	fbio	Discontinued Operation Gain Loss On Disposal Of National Net Of Tax DiscontinuedOperationGainLossOnDisposalOfNationalNetOfTax	0
CY2018Q4	fbio	Discontinued Operation Gain Loss On Disposal Of National Net Of Tax DiscontinuedOperationGainLossOnDisposalOfNationalNetOfTax	2333000
CY2018Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-2077000
CY2018Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-6924000
CY2018Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	2648000
CY2018Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-7116000
CY2017Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	3034000
CY2017Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-184000
CY2017Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-3961000
CY2017Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1212000
CY2017	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	4442
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	93823000
CY2018Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	0
CY2018Q4	fbio	Deferred Tax Assets Amortization Of Upfront Fees DeferredTaxAssetsAmortizationOfUpfrontFees	12552000
CY2018Q4	fbio	Deferred Tax Assets Amortization Of In Process Research And Development DeferredTaxAssetsAmortizationOfInProcessResearchAndDevelopment	420000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	10404000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2267000
CY2018Q4	fbio	Return Reserve ReturnReserve	2400000
CY2017Q4	fbio	Return Reserve ReturnReserve	1200000
CY2017Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	0
CY2017Q4	fbio	Deferred Tax Assets Start Up Costs1 DeferredTaxAssetsStartUpCosts1	0
CY2018Q3	us-gaap	Share Price SharePrice	3.04
CY2018Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	164473
CY2018	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	500000
CY2018	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	10200000
CY2018Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	130100000
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13100000
CY2019Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	4000000
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2018	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	7921
CY2018	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2419
CY2018	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	10340
CY2017	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	104
CY2017	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	7687
CY2017	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3141
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.05
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.03
CY2018	fbio	Effective Income Tax Rate Reconciliation Provision For Return EffectiveIncomeTaxRateReconciliationProvisionForReturn	-0.01
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.01
CY2018	fbio	Effective Income Tax Rate Reconciliation Change In State Rate Percent EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent	-0.03
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.25
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	0.01
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	10207000
CY2018Q4	fbio	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	55000
CY2018Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	805000
CY2018Q4	fbio	Deferred Tax Assets Start Up Costs1 DeferredTaxAssetsStartUpCosts1	2535000
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	133068000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	132114000
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	954000
CY2018Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	0
CY2018Q4	us-gaap	Deferred Tax Liabilities Parents Basis In Discontinued Operation DeferredTaxLiabilitiesParentsBasisInDiscontinuedOperation	954000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	0
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2018	dei	Document Type DocumentType	10-K
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018	dei	Entity Registrant Name EntityRegistrantName	Fortress Biotech, Inc.
CY2018	dei	Entity Central Index Key EntityCentralIndexKey	0001429260
CY2018	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2018Q2	dei	Entity Public Float EntityPublicFloat	94124331
CY2018	dei	Trading Symbol TradingSymbol	FBIO
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	61302251
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2018	dei	Entity Small Business EntitySmallBusiness	true
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0
CY2018	fbio	Effective Income Tax Rate Reconciliation Change In Federal Rate Percent EffectiveIncomeTaxRateReconciliationChangeInFederalRatePercent	0
CY2018	fbio	Effective Income Tax Rate Reconciliation Intercompany Elimination Adjustments Percent EffectiveIncomeTaxRateReconciliationIntercompanyEliminationAdjustmentsPercent	0
CY2018	fbio	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantsPercent	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0

Files In Submission

Name	View Source	Status
0001144204-19-014617-index-headers.html	Edgar Link	pending
0001144204-19-014617-index.html	Edgar Link	pending
0001144204-19-014617.txt	Edgar Link	pending
0001144204-19-014617-xbrl.zip	Edgar Link	pending
fbio-20181231.xml	Edgar Link	completed
fbio-20181231.xsd	Edgar Link	pending
fbio-20181231_cal.xml	Edgar Link	unprocessable
fbio-20181231_def.xml	Edgar Link	unprocessable
fbio-20181231_lab.xml	Edgar Link	unprocessable
fbio-20181231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv514739_10k.htm	Edgar Link	pending
tv514739_ex10-3.htm	Edgar Link	pending
tv514739_ex21-1.htm	Edgar Link	pending
tv514739_ex23-1.htm	Edgar Link	pending
tv514739_ex31-1.htm	Edgar Link	pending
tv514739_ex31-2.htm	Edgar Link	pending
tv514739_ex32-1.htm	Edgar Link	pending
tv514739_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FBIO
Fortress Biotech, Inc. Stock $fbio

2019 Q1 Form 10-K Financial Statement

#000114420419014617 Filed on March 18, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO Fortress Biotech, Inc. Stock $fbio

2019 Q1 Form 10-K Financial Statement

#000114420419014617 Filed on March 18, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO
Fortress Biotech, Inc. Stock $fbio